Abstract
BackgroundDespite the survival benefits observed with immune checkpoint blockade (ICB) treatment—programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1), many patients with cancer have not benefited from these agents because of impaired...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have